IRA likely to lead to higher drug list prices and bigger rebates, Congressional Budget Office predicts

Lia DeGroot

The Congressional Budget Office expects that drugmakers will raise their prices and offer larger rebates for new drugs because of provisions in the Inflation Reduction …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

IRA likely to lead to higher drug list prices and bigger rebates, Congressional Budget Office predicts

Lia DeGroot

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

IRA like­ly to lead to high­er drug list prices and big­ger re­bates, Con­gres­sion­al Bud­get Of­fice pre­dicts

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

IRA likely to lead to higher drug list prices and bigger rebates, Congressional Budget Office predicts